HAIRY CELL LEUKEMIA
Dear friends,
Wishing you a very happy and prosperous New Year 2021.
Hairy cell leukemia (HCL) is a chronic B- cell lymphoid malignancy that has always fascinated hematologists and pathologists. In this post, we shall see about the history of hairy cell leukemia with landmark papers.
Year
|
Description
|
Landmark
papers |
1952 |
Reticular
cell leukemia: A clinical hematologic entity- described 17 patients with
typical features of HCL presented at a meeting at American Society for
Clinical Pathology. |
Rosenthal
|
1958 |
Classical
description of the disease as Leukaemic Reticulo-endotheliosis and the
benefits of splenectomy. |
Bouroncle
et al |
1966 |
Introduction
of the term ‘Hairy cell’ |
Schrek
and Donelly |
1966 |
Demonstration
of the characteristic bone marrow fibrosis in HCL |
Duhamel
and Guerra |
1971 |
Showed
that hairy cells stained with Tartrate-resistant acid phosphatase (TRAP)
Isoenzyme 5 |
Yam
et al |
1972 |
Electron
microscopy description of ribosome-lamella complex (RLC) |
Katayama,
Li and Yam |
1974 |
Pattern
of bone marrow histology described |
Burke
et al |
1974 |
B-
cell nature of NHLs confirmed |
Catovsky
et al |
1978 |
Prognosis-
Median OS four years |
Golomb,
Catovsky |
1979 |
Splenectomy
in 26 patients: 86% OS at five years in responders |
Mintz
and Golomb |
1982 |
Clinical
staging system: prognostic groups based on anemia and splenomegaly |
Jansen
and Hermans |
1983 |
The genetic B-cell origin of
HCL |
Korsmeyer
et al |
1984 |
The
membrane phenotype of HCL |
Melo
et al |
1984 |
Results
of treatment of HCL with interferon –alpha |
Quesada
et al |
1987 |
UK
experience with alpha interferon |
Worman,
Catovsky , Cawley et al. |
1987 |
Results
of treatment of HCL with pentostatin |
Spiers
et al. |
1990 |
Results
of treatment with 2CDA (2-chloro deoxy adenosine) (Cladribine) |
Piro
et al |
1990 |
CD 103 expression in HCL |
Mulligan
et al |
1995 |
Randomized
trial of pentostatin vs interferon in HCL |
Grever
et al |
2004 |
Annexin A1 expression in HCL |
Falini
et al |
2009 |
Long-term
follow up of 233 HCL patients treated with pentostatin or CDA |
Else
et al |
2011 |
Demonstrated BRAF V 600
mutation in 100 % cases |
Tiacci
et al |
2015 |
Clinical
trials demonstrating effectiveness of BRAF inhibitors |
Tiacci
et al |
2015 |
Clonal
mutations of CDKN1B (p27), a cell cycle inhibitor, in 16 % of cases |
Dietrich
et al |
2016 |
CDA
+ R (Rituximab) vs CDA alone, showing benefit
of addition of rituximab |
Chihara
D et al |
2018 |
Pivotal
trial of moxetumomab pasudotox in HCL |
Kreitman
et al |
Electron microscopic
picture of Hairy cells within splenic cord. Picture taken from Hairy cell
leukemia (Leukemic reticuloendotheliosis). II. Ultrastructure of the spleen. Jerome
S. Burkem, Brucem Ackaym. Cancer,1976.
There has been remarkable progress made over years in the diagnosis and management of HCL with the median overall survival of just around four years, in 1978 to a median relapse free survival of 16 years now. We shall see in detail in subsequent posts about the treatment of hairy cell leukemia.
Wishing you all again a very happy, prosperous and successful
new year 2021.
References:
Hairy cell leukemia: From Hairy Beginnings to a BRAF New World.
British Society for hematology. 60th anniversary special issue. November 2020.
Written by
Dr.Priyavadhana B
Very nice presentation of HCL History, Diagnostic and Therapeutic evolution.
ReplyDeleteA Very Happy and Propsperous New Year
Hi thanks Dr.Sravani. Wish you a very happy new year.
DeleteVery informative and interesting.
ReplyDeleteThanks Dr.Deepak
Delete